nonlinear mixed-effects modeling method by nonmem version 7.5.0 (ICON plc)
90
Structured Review
ICON plc
nonlinear mixed-effects modeling method by nonmem version 7.5.0
Nonlinear Mixed Effects Modeling Method By Nonmem Version 7.5.0, supplied by ICON plc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nonlinear+mixed-effects+modeling+method/nonlinear+mixed+effects+modeling+software+nonmem+version+7+4+4/pm35461968-142-15-22
Average 90 stars, based on 1 article reviews
Nonlinear Mixed Effects Modeling Method By Nonmem Version 7.5.0, supplied by ICON plc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nonlinear+mixed-effects+modeling+method/nonlinear+mixed+effects+modeling+software+nonmem+version+7+4+4/pm35461968-142-15-22
Average 90 stars, based on 1 article reviews
nonlinear mixed-effects modeling method by nonmem version 7.5.0 - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
other:Article Title: Population pharmacokinetics and IVIVC for mesalazine enteric-coated tablets. Article Snippet: Although in-vivo bioequivalence (BE) study serves as a golden standard for establishing interchangeability of oral dosage forms, it remains challenging for products with high inter-subject variability such as mesalazine enteric-coated tablet to fulfil the BE criteria set by regulatory authorities.. Mesalazine, as a BCS class IV drug, targets to be delivered to distal ileum or colon with a pH-sensitive polymer coating for the remission of ulcerative colitis.. Through population pharmacokinetic (PK) analysis and in-vitro in-vivo correlation (IVIVC) modeling on the dissolution and BE data of a generic enteric-coated product (EM) and its reference Salofalk® 250 mg tablet (SM), we for the first time revealed the underlying mechanism of the high inter-subject variability for such delayed-release formulation. |
